Sandoz is a global leader in generic pharmaceuticals and biosimilars. With so many people around the world trusting us with their health, we have an enormous responsibility to deliver the highest quality products and to seek novel approaches to help people gain greater access to medicine. Our products reach approximately 500 million patients per year 1.
Discovering new ways to improve and extend people’s lives.
Sandoz can trace its history to the foundation of Kern & Sandoz in Switzerland in 1886. Historical highlights related to the Sandoz brand include the launch of Calcium Sandoz in 1929, the first oral penicillin in 1951, and the 1972 discovery of the immunosuppressive effect of cyclosporin, which today is used in transplantation. Biosimilars, approved biologics with comparable safety, quality, and efficacy to a reference product, are another example of our innovative capacity.
While biologics provide a revolutionary treatment option for many diseases, their growing demand combined with historically limited competition strains healthcare budgets and limits patient access. Biosimilars increase patient access to biologics while reducing healthcare system costs. Sandoz has been developing biosimilars since 1996 and achieved several firsts along the way, including the first biosimilar in Europe (Omnitrope in 2006) and the United States (Zarxio in 2015).
We go beyond providing standard products but also add value to the healthcare system through a range of support services and value-added medicines.
Consistent high quality is critical to ensure our sustainable business performance and growth. We strive to continually improve standards and processes in order to meet and exceed stakeholder expectations.